(Q44164148)

30 November 2017

Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients (English)

1 reference

30 November 2017

0 references

0 references

5

1 reference

30 November 2017

6

Gavin Giovannoni

1 reference

30 November 2017

1

Konrad Rejdak

1 reference

PubMed ID

12359324

30 November 2017

Halina Bartosik-Psujek

series ordinal

2

object named as

Halina Bartosik-Psujek

1 reference

30 November 2017

4

Tomasz Kocki

1 reference

30 November 2017

7

Waldemar A Turski

1 reference

30 November 2017

8

Zbigniew Stelmasiak

1 reference

30 November 2017

Beata Dobosz

3

1 reference

PubMed ID

12359324

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

30 November 2017

3

1 reference

inferred from page(s)

published in

Neuroscience Letters

1 reference

30 November 2017

331

1 reference

30 November 2017

1

1 reference

30 November 2017

63-65

1 reference

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Cortical cerebral metabolism correlates with MRI lesion load and cognitive dysfunction in MS

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Oligodendrocyte killing by quinolinic acid in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Metabolic control of kynurenic acid formation in the rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Amino acid concentrations in cerebrospinal fluid of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Autoimmune encephalomyelitis ameliorated by AMPA antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Kynurenines in the CNS: from endogenous obscurity to therapeutic importance

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Identification and quantification of kynurenic acid in human brain tissue.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Formation of endogenous glutamatergic receptors antagonist kynurenic acid--differences between cortical and spinal cord slices

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3940%2802%2900710-3

7 January 2021

10.1016/S0304-3940(02)00710-3

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

12359324